Expert consensus on the diagnosis and treatment strategies for advanced esophageal squamous cell carcinoma following progression on first-line immunochemotherapy in Sichuan Province

doi:10.3760/cma.j.cn371439-20241203-00047

Abstract

Abstract:

The disease burden of esophageal cancer in China ranks first in the world， with significant regional differences in incidence. Sichuan province is facing a more complicated and severe situation， with a high incidence of esophageal cancer. Although first-line immunotherapy combined with chemotherapy for advanced esophageal squamous cell carcinoma has been widely used clinically， but there is no unified standard and consensus on the treatment of disease progression after immune resistance. The treatment strategy of city-level hospitals is somewhat disordered. In light of this， the Esophageal Cancer Professional Committee of the Sichuan Anti-Cancer Association， in conjunction with multidisciplinary experts in the field of esophageal cancer research in Sichuan province， has developed this consensus. The consensus refers to domestic and foreign guidelines， consensus， and the latest evidence-based clinical evidence， combined with clinical practice experience， with the aim of providing scientific and standardized guidance for clinicians. It is hoped to further improve the treatment outcomes and quality of life for patients with advanced esophageal squamous cell carcinoma and promote the advancement of esophageal cancer diagnosis and treatment in Sichuan province.

Key words: Esophageal squamous cell carcinoma, Immune checkpoint inhibitors, Drug resistance, Disease progression, Treatment strategy, Expert consensus

Esophageal Cancer Professional Committee of the Sichuan Anti-Cancer Association. Expert consensus on the diagnosis and treatment strategies for advanced esophageal squamous cell carcinoma following progression on first-line immunochemotherapy in Sichuan Province[J]. Journal of International Oncology, 2025, 52(5): 273-281.

Figures/Tables 2

References 48

[1]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. DOI: 10.3760/cma.j.cn112152-20240119-00035.
[2]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管鳞状细胞癌新辅助放射治疗专家共识[J]. 国际肿瘤学杂志, 2023, 50(3): 129-137. DOI: 10.3760/cma.j.cn371439-20230217-00027.
[3]	吴浦嫄, 祁亮, 王涛, 等. 基于高频复发区改良临床靶区的术后放疗在食管鳞状细胞癌中的疗效研究[J]. 国际肿瘤学杂志, 2022, 49(8): 464-472. DOI: 10.3760/cma.j.cn371439-20220524-00090.
[4]	中华人民共和国国家卫生健康委员会医政医管局. 食管癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21(10): 1247-1268. DOI: 10.3760/cma.j.cn115610-20220726-00433.
[5]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)食管癌诊疗指南2019[M]. 北京: 人民卫生出版社, 2019.
[6]	Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline[J]. J Clin Oncol, 2020, 38(16): 1849-1863. DOI: 10.1200/JCO.19.03120. pmid: 32058842
[7]	Committee EG. ESMO-consensus-conferences-standard-operating-procedures-january[Z]. 2022.
[8]	Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics[J]. Lancet Oncol, 2017, 18(3): e143-e152. DOI: 10.1016/S1470-2045(17)30074-8.
[9]	Tazdait M, Mezquita L, Lahmar J, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria[J]. Eur J Cancer, 2018, 88: 38-47. DOI: 10.1016/j.ejca.2017.10.017. pmid: 29182990
[10]	陆波, 高蔚, 王瑞, 等. PET/CT对非小细胞肺癌患者纵隔淋巴结转移的诊断效能[J]. 中国医师杂志, 2024, 26(5): 733-737. DOI: 10.3760/cma.j.cn431274-20230719-00019.
[11]	丘文明, 肖国有. PET/CT在食管癌诊疗中的应用现状及潜在价值[J]. 微创医学, 2022, 17(6): 669-675. DOI: 10.11864/j.issn. 1673.2022.06.01.
[12]	Howard BA, Wong TZ. ¹⁸F-FDG-PET/CT imaging for gastrointestinal malignancies[J]. Radiol Clin North Am, 2021, 59(5): 737-753. DOI: 10.1016/j.rcl.2021.06.001.
[13]	Peng D, He J, Liu H, et al. FAPI PET/CT research progress in digestive system tumours[J]. Dig Liver Dis, 2022, 54(2): 164-169. DOI: 10.1016/j.dld.2021.07.011.
[14]	Schoenfeld AJ, Antonia SJ, Awad MM, et al. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer[J]. Ann Oncol, 2021, 32(12): 1597-1607. DOI: 10.1016/j.annonc.2021.08.2151. pmid: 34487855
[15]	Kluger HM, Tawbi HA, Ascierto ML, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce[J]. J Immunother Cancer, 2020, 8(1): e000398. DOI: 10.1136/jitc-2019-000398.
[16]	Rizvi N, Ademuyiwa FO, Cao ZA, et al. Society for immunotherapy of cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy[J]. J Immunother Cancer, 2023, 11(3): e005920. DOI: 10.1136/jitc-2022-005920.
[17]	中国临床肿瘤学会非小细胞肺癌专业委员会. 驱动基因阴性晚期非小细胞肺癌一线免疫治疗耐药评估及治疗策略中国专家共识(2024版)[J]. 中华医学杂志, 2024, 104(6): 411-426. DOI: 10.3760/cma.j.cn112137-20230927-00589.
[18]	Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 832-842. DOI: 10.1016/S1470-2045(20)30110-8. pmid: 32416073
[19]	Xu J, Li Y, Fan Q, et al. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)[J]. Nat Commun, 2022, 13(1): 857. DOI: 10.1038/s41467-022-28408-3.
[20]	Shen L, Kato K, Kim SB, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase Ⅲ study[J]. J Clin Oncol, 2022, 40(26): 3065-3076. DOI: 10.1200/JCO.21.01926.
[21]	林岚. PD-1/PD-L1抑制剂vs. 化疗在晚期食管癌二线治疗疗效及安全性: 一项基于RCT研究的Meta分析[D]. 福州: 福建医科大学, 2021. DOI: 10.27020/d.cnki.gfjyu.2021.000738.
[22]	冯国良. 免疫治疗对比化疗二线治疗食管鳞癌的疗效性和安全性的meta分析[D]. 南昌: 南昌大学, 2021. DOI: 10.27232/d.cnki.gnchu.2021.003860.
[23]	Wang F, Lin C, Sun J, et al. 1020MO-AdvanTIG-203: phase Ⅱ randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity[J]. Ann Oncol, 2023, 34(Sup2): S621. DOI: 10.1016/j.annonc.2023.09. 2159.
[24]	Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2023, 24(5): 483-495. DOI: 10.1016/S1470-2045(23)00108-0. pmid: 37080222
[25]	Huang J, Hong YG, Liu J, et al. The feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): update results of a retrospective exploratory study[J]. ASCO, 2024, 42: e16606. DOI: 10.1200/JCO.2024.42.16_suppl.e16006.
[26]	Wang F, Wang JS, Meng XR, et al. Camrelizumab plus apatinib for immunochemotherapy-treated advanced esophageal squamous cell carcinoma: preliminary results of cohort 2 in CAP 02 study[J]. J Clin Oncol, 2023, 41(Sup4): 384. DOI: 10.1200/JCO.2023.41.4_suppl.384.
[27]	Meng X, Wang J, Jin X. Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (CAP 02 Rechallenge): a single-arm multicenter, phase Ⅱ trial[J]. J Clin Oncol, 2024, 42(Sup3): 364. DOI: 10.1200/JCO.2024.42.3_suppl.364.
[28]	Kok PS, Cho D, Yoon WH, et al. Validation of progression-free survival rate at 6 months and objective response for estimating overall survival in immune checkpoint inhibitor trials: a systematic review and meta-analysis[J]. JAMA Netw Open, 2020, 3(9): e2011809. DOI: 10.1001/jamanetworkopen.2020.11809.
[29]	NCCN. Management of immunotherapy-related toxicities[EB/OL]. [2024-11-21]. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1486.
[30]	Atkins MB, Ascierto PA, Feltquate D, et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies[J]. J Immunother Cancer, 2023, 11(3): e005923. DOI: 10.1136/jitc-2022-005923.
[31]	Gao X, Xu N, Li Z, et al. Safety and antitumour activity of cado-nilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial[J]. Lancet Oncol, 2023, 24(10): 1134-1146. DOI: 10.1016/S1470-2045(23)00411-4.
[32]	WCGI. Poster session p-162[Z]. 2023.
[33]	Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation[J]. Lancet Oncol, 2020, 21(1): e18-e28. DOI: 10.1016/S1470-2045(19)30718-1.
[34]	中国抗癌协会肿瘤放射治疗专业委员会, 中华医学会放射肿瘤治疗学分会, 中国医师协会放射肿瘤治疗医师分会. 食管癌放疗联合免疫治疗专家共识(2023年版)[J]. 中华放射医学与防护杂志, 2023, 43(8): 575-587. DOI: 10.3760/cma.j.cn112271-2023 0626-00207.
[35]	Zhuo N, Liu C, Zhang Q, et al. Characteristics and prognosis of acquired resistance to immune checkpoint inhibitors in gastrointestinal cancer[J]. JAMA Netw Open, 2022, 5(3): e224637. DOI: 10. 1001/jamanetworkopen.2022.4637.
[36]	Duan Y, Qin W, Yang L, et al. Safety and efficacy of concurrent or sequential radiotherapy plus (PD-1) inhibitors in oligometastatic esophageal cancer[J]. Cancer Manag Res, 2023, 15: 55-65. DOI: 10.2147/CMAR.S391529. pmid: 36685716
[37]	Liu Q, Chen J, Lin Y, et al. Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2024, 9(1): 45-55. DOI: 10.1016/S2468-1253(23)00316-3.
[38]	Zhao W, Ke S, Cai X, et al. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: an open-label, single-arm, phase Ⅱ trial[J]. Radiother Oncol, 2023, 184: 109679. DOI: 10.1016/j.radonc.2023.109679.
[39]	Li J, Wen Y, Xiang Z, et al. Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer[J]. Radiother Oncol, 2021, 154: 201-206. DOI: 10.1016/j.radonc. 2020.09.042. pmid: 32980382
[40]	Liu Q, Zhu Z, Chen Y, et al. Phase 2 study of stereotactic body radiation therapy for patients with oligometastatic esophageal squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2020, 108(3): 707-715. DOI: 10.1016/j.ijrobp.2020.05.003.
[41]	Wu L, Li B, Wan G, et al. Toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: a single-arm phase 2 trial[J]. Nat Commun, 2024, 15(1): 7116. DOI: 10.1038/s41467-024-51105-2.
[42]	Li ZC, Sun YT, Lai MY, et al. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: a systematic review and network meta-analysis[J]. Int Immunopharmacol, 2022, 109: 108790. DOI: 10. 1016/j.intimp.2022.108790.
[43]	Chen J, Luo S, Qin S, et al. Pembrolizumab vs. chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line therapy: analysis of the Chinese subgroup in KEYNOTE-181[J]. Ann Oncol, 2019, 30(Sup5): 294. DOI: 10.1093/annonc/mdz247.086.
[44]	Kojima T, Shah MA, Muro K, et al. Randomized phase Ⅲ KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer[J]. J Clin Oncol, 2020, 38(35): 4138-4148. DOI: 10.1200/JCO.20.01888.
[45]	李涛, 李宝生, 吕家华, 等. 食管癌患者营养治疗指南[J]. 肿瘤代谢与营养电子杂志, 2020, 7(1): 32-42. DOI: 10.16689/j.cnki.cn11-9349/r.2020.01.007.
[46]	中国抗癌协会肿瘤营养专业委员会, 中华医学会肠外肠内营养学分会, 中国医师协会放射肿瘤治疗医师分会营养与支持治疗学组. 食管癌患者营养治疗指南[J]. 中国肿瘤临床, 2020, 47(1): 1-6. DOI: 10.3969/j.issn.1000-8179.2020.01.430.
[47]	Yu FJ, Shih HY, Wu CY, et al. Enteral nutrition and quality of life in patients undergoing chemoradiotherapy for esophageal carcinoma: a comparison of nasogastric tube, esophageal stent, and ostomy tube feeding[J]. Gastrointest Endosc, 2018, 88(1): 21-31.e4. DOI: 10. 1016/j.gie.2017.11.030.
[48]	Anderson PM, Lalla RV. Glutamine for amelioration of radiation and chemotherapy associated mucositis during cancer therapy[J]. Nutrients, 2020, 12(6): 1675. DOI: 10.3390/nu12061675.

证据水平	定义
Ⅰ	至少1项方法学质量良好（产生偏倚可能性小）的大规模随机对照试验或对多项没有非均一性且良好实施随机试验的Meta分析提供的证据
Ⅱ	小规模随机试验或怀疑有偏倚（方法学质量较差）的大规模随机试验，或对这些试验或多项有非均一性的试验的Meta分析
Ⅲ	前瞻性队列研究
Ⅳ	回顾性队列研究或病例对照研究
Ⅴ	没有对照组的研究、病理报告、专家观点